Development and in vivo preclinical validation of [18F]FLUSONIM, a highly hydrophilic 18F-labelled 2-nitroimidazole derivative for high performance hypoxia PET imaging - Normandie Université Accéder directement au contenu
Communication Dans Un Congrès Année : 2020

Development and in vivo preclinical validation of [18F]FLUSONIM, a highly hydrophilic 18F-labelled 2-nitroimidazole derivative for high performance hypoxia PET imaging

Fichier non déposé

Dates et versions

hal-02489356 , version 1 (24-02-2020)

Identifiants

  • HAL Id : hal-02489356 , version 1

Citer

C. Maingueneau, A.-E. Lafargue, F. Fillesoye, J. Toutain, S. Valable, et al.. Development and in vivo preclinical validation of [18F]FLUSONIM, a highly hydrophilic 18F-labelled 2-nitroimidazole derivative for high performance hypoxia PET imaging. 4th Nuclear Technologies for Health Symposium, NTHS2020, Feb 2020, Nantes, France. ⟨hal-02489356⟩
58 Consultations
4 Téléchargements

Partager

Gmail Facebook X LinkedIn More